Further, some studies have documented that aberrant expression of myeloid antigens (CD13 and CD33) is associated with better prognosis while that of T-cell antigens (CD5 and CD7) is associated with worse prognosis in B-ALL (Hussein et al., 2011; Ibrahim et al., 2017). The gene discussed is CD5; the disease is acute lymphoblastic leukemia.